MEDP * Stock Overview
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Medpace Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6,565.00 |
| 52 Week High | US$6,565.00 |
| 52 Week Low | US$3,658.59 |
| Beta | 1.4 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | 73.68% |
| 3 Year Change | 102.12% |
| 5 Year Change | 516.82% |
| Change since IPO | 552.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDP * | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 73.7% | 0% | 0% |
Return vs Industry: MEDP * exceeded the MX Life Sciences industry which returned -5.4% over the past year.
Return vs Market: MEDP * exceeded the MX Market which returned 2.4% over the past year.
Price Volatility
| MEDP * volatility | |
|---|---|
| MEDP * Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: MEDP * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MEDP *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 5,800 | August Troendle | www.medpace.com |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medpace Holdings, Inc. Fundamentals Summary
| MEDP * fundamental statistics | |
|---|---|
| Market cap | Mex$205.95b |
| Earnings (TTM) | Mex$5.30b |
| Revenue (TTM) | Mex$33.31b |
38.9x
P/E Ratio6.2x
P/S RatioIs MEDP * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDP * income statement (TTM) | |
|---|---|
| Revenue | US$1.96b |
| Cost of Revenue | US$658.67m |
| Gross Profit | US$1.30b |
| Other Expenses | US$991.82m |
| Earnings | US$312.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.10 |
| Gross Margin | 66.44% |
| Net Profit Margin | 15.91% |
| Debt/Equity Ratio | 0% |
How did MEDP * perform over the long term?
See historical performance and comparison